Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2018) 56 P502 | DOI: 10.1530/endoabs.56.P502


Clinical Centre of Montenegro, Podgorica, Montenegro.

Introduction: American Heart Association considers diabetes mellitus (DM) to be one of seven major controllable risk factors for cardiovascular disease. At least 68% of patients age 65 or older with DM die from some form of heart disease while 16% die as a consequence of stroke. Studies conducted in patients with type 2 DM (T2DM) have not confirmed a significant association between a certain types of glucose-lowering drugs and a presence of cardiovascular events.

Aim: To establish a relationship between different treatment regimens in patients with T2DM and a presence of acute or recent cardiovascular event.

Methodology: A cross sectional population based study included patients with both T2DM and myocardial infarction- acute or in the past 1 year, that have been examined in Clinical center of Montenegro during one day. Demographic data were collected, along with a type of treatment for T2DM and current glycoregulation. Statistical analysis was performed using descriptive statistics and Student t-test.

Results: Out of 42 subjects included in study, 23 were female and 19 were male, mean age 66.78±9.67 years. Insulin therapy solely was present in 10 patients (23.8%), combined therapy in 21 (50%) and oral glucose-lowering agents in 11 (26.2%) of patients. The mean value of glycated hemoglobin (HbA1c) in groups respectively was 9.0%, 8.9% and 6.97%. No statistical significance was found between insulin and combined therapy (P=0.8691), while there were a significant statistical differences between insulin and oral therapy (P=0.0020) and combined and oral therapy (P=0.0021).

Conclusion: Glycated hemoglobin, however, could not be a valid surrogate for assessing either the cardiovascular risks or benefits related to diabetes therapy. We concerned that some glucose-lowering agents may impact greater cardiovascular risk but there is no sufficient evidence to support one drug or any combination of other drugs for the reduction of cardiovascular events.

Volume 56

20th European Congress of Endocrinology

Barcelona, Spain
19 May 2018 - 22 May 2018

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.